Skip to main content
Top
Published in: Journal of Cancer Education 2/2018

01-04-2018

Quantitative Information on Oncology Prescription Drug Websites

Authors: Helen W. Sullivan, Kathryn J. Aikin, Linda B. Squiers

Published in: Journal of Cancer Education | Issue 2/2018

Login to get access

Abstract

Our objective was to determine whether and how quantitative information about drug benefits and risks is presented to consumers and healthcare professionals on cancer-related prescription drug websites. We analyzed the content of 65 active cancer-related prescription drug websites. We assessed the inclusion and presentation of quantitative information for two audiences (consumers and healthcare professionals) and two types of information (drug benefits and risks). Websites were equally likely to present quantitative information for benefits (96.9 %) and risks (95.4 %). However, the amount of the information differed significantly: Both consumer-directed and healthcare-professional-directed webpages were more likely to have quantitative information for every benefit (consumer 38.5 %; healthcare professional 86.1 %) compared with every risk (consumer 3.1 %; healthcare professional 6.2 %). The numeric and graphic presentations also differed by audience and information type. Consumers have access to quantitative information about oncology drugs and, in particular, about the benefits of these drugs. Research has shown that using quantitative information to communicate treatment benefits and risks can increase patients’ and physicians’ understanding and can aid in treatment decision-making, although some numeric and graphic formats are more useful than others.
Literature
1.
go back to reference Abel GA, Burstein HJ, Hevelone ND, Weeks JC (2009) Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. J Clin Oncol 27:4182–4187CrossRefPubMedPubMedCentral Abel GA, Burstein HJ, Hevelone ND, Weeks JC (2009) Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. J Clin Oncol 27:4182–4187CrossRefPubMedPubMedCentral
2.
go back to reference Viale PH, Yamamoto DS (2004) The attitudes and beliefs of oncology nurse practitioners regarding direct-to-consumer advertising of prescription medications. Oncol Nurs Forum 31:777–783CrossRefPubMed Viale PH, Yamamoto DS (2004) The attitudes and beliefs of oncology nurse practitioners regarding direct-to-consumer advertising of prescription medications. Oncol Nurs Forum 31:777–783CrossRefPubMed
3.
go back to reference Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Tamura K, Fujiwara Y (2012) Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal. PLoS One 7(8):e44393CrossRefPubMedPubMedCentral Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Tamura K, Fujiwara Y (2012) Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal. PLoS One 7(8):e44393CrossRefPubMedPubMedCentral
5.
go back to reference Schwartz LM, Woloshin S (2013) The drug facts box: improving the communication of prescription drug information. Proc Natl Acad Sci 110(3):14069–14074CrossRefPubMedPubMedCentral Schwartz LM, Woloshin S (2013) The drug facts box: improving the communication of prescription drug information. Proc Natl Acad Sci 110(3):14069–14074CrossRefPubMedPubMedCentral
6.
go back to reference Korenstein D, Keyhani S, Mendelson A, Ross JS (2011) Adherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribing. PLoS One 6:e23336CrossRefPubMedPubMedCentral Korenstein D, Keyhani S, Mendelson A, Ross JS (2011) Adherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribing. PLoS One 6:e23336CrossRefPubMedPubMedCentral
7.
go back to reference West SL, Squiers LB, McCormack L, Southwell BG, Brouwer ES, Ashok M, Lux L, Boudewyns V, O’Donoghue A, Sullivan HW (2013) Communicating quantitative risks and benefits in promotional prescription drug labeling or print advertising. Pharmacoepidemiol Drug Saf 22(5):447–458CrossRefPubMed West SL, Squiers LB, McCormack L, Southwell BG, Brouwer ES, Ashok M, Lux L, Boudewyns V, O’Donoghue A, Sullivan HW (2013) Communicating quantitative risks and benefits in promotional prescription drug labeling or print advertising. Pharmacoepidemiol Drug Saf 22(5):447–458CrossRefPubMed
8.
go back to reference Sullivan HW, O’Donoghue AC, Aikin KJ (2015) Communicating benefit and risk information in direct-to-consumer print advertisements: a randomized study. Ther Innov Regul Sci 49:493–502CrossRef Sullivan HW, O’Donoghue AC, Aikin KJ (2015) Communicating benefit and risk information in direct-to-consumer print advertisements: a randomized study. Ther Innov Regul Sci 49:493–502CrossRef
9.
go back to reference Covey J (2007) A meta-analysis of the effects of presenting treatment benefits in different formats. Med Decis Mak 27:638–654CrossRef Covey J (2007) A meta-analysis of the effects of presenting treatment benefits in different formats. Med Decis Mak 27:638–654CrossRef
10.
go back to reference Lipkus I (2007) Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Mak 27:697–713CrossRef Lipkus I (2007) Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Mak 27:697–713CrossRef
11.
go back to reference Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, Kaatz S, Mann DM, Sussman JB, Korenstein D, Schardt C, Nagi A, Sloane R, Feldstein DA (2014) Evidence-based risk communication: a systematic review. Ann Intern Med 161:270–280CrossRefPubMed Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, Kaatz S, Mann DM, Sussman JB, Korenstein D, Schardt C, Nagi A, Sloane R, Feldstein DA (2014) Evidence-based risk communication: a systematic review. Ann Intern Med 161:270–280CrossRefPubMed
12.
go back to reference Abel GA, Lee SJ, Weeks JC (2007) Direct-to-consumer advertising in oncology: a content analysis of print media. J Clin Oncol 25(10):1267–1271CrossRefPubMed Abel GA, Lee SJ, Weeks JC (2007) Direct-to-consumer advertising in oncology: a content analysis of print media. J Clin Oncol 25(10):1267–1271CrossRefPubMed
13.
go back to reference Davis JJ (2012) Content analysis of efficacy descriptions on branded pharmaceutical websites. J Med Mark 12(4):211–220CrossRef Davis JJ (2012) Content analysis of efficacy descriptions on branded pharmaceutical websites. J Med Mark 12(4):211–220CrossRef
14.
go back to reference Woloshin S, Schwartz LM, Tremmel J, Gilbert Welch H (2001) Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? Lancet 358(9288):1141–1146CrossRefPubMed Woloshin S, Schwartz LM, Tremmel J, Gilbert Welch H (2001) Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? Lancet 358(9288):1141–1146CrossRefPubMed
15.
go back to reference Kontos EZ, Viswanath K (2011) Cancer-related direct-to-consumer advertising: a critical review. Nat Rev Cancer 11(2):142–150CrossRefPubMed Kontos EZ, Viswanath K (2011) Cancer-related direct-to-consumer advertising: a critical review. Nat Rev Cancer 11(2):142–150CrossRefPubMed
Metadata
Title
Quantitative Information on Oncology Prescription Drug Websites
Authors
Helen W. Sullivan
Kathryn J. Aikin
Linda B. Squiers
Publication date
01-04-2018
Publisher
Springer US
Published in
Journal of Cancer Education / Issue 2/2018
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-016-1107-1

Other articles of this Issue 2/2018

Journal of Cancer Education 2/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine